This study establishes a connection between the MEF2D-ACSL3 axis and the prevention of ferroptosis, as well as sorafenib resistance, for the first time, addressing a gap in the mechanisms of resistance in HCC. This evidence concerns the gene MEF2D and hepatocellular carcinoma.